1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Pfizer Skeptical About Value-Based Contracting In Current Environment

 
• By Cathy Kelly

'We have about 18 different projects underway but we've achieved' only one value-based deal, Pfizer CEO Ian Read says. 'The risks and incentives have to be with the providers. … That's how you get the best health care.'

Hitting bigger business target

Pfizer Inc. has been slower than some of its peers in executing value-based contracts with payers and that's because it believes that meaningful deals aren't very workable in the current system, Chairman and CEO Ian Read suggested during a policy discussion on health care system value in Washington, DC Sept. 19.

"We've been struggling to do value-based contracting with payers and providers," he said. "We have about 18 different projects underway...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Pricing Debate

Colorado Board Adopts Medicare Maximum Fair Price For Enbrel, Assumes Amgen ‘Amenable’

 
• By Cathy Kelly

The state’s prescription drug affordability board could be the first to recommend an upper payment limit for a prescription drug.

Medicare Part D Plans Turn to Coinsurance, Higher Deductibles Amid IRA Changes

 
• By Tim Casey

Newly implemented IRA provisions may not necessarily lower drug costs for those enrolled in Medicare Part D plans, according to research by the USC Schaeffer Center for Health Policy and Economics.

Pharma’s Move Into Direct-To-Patient Sales Facing Legal, Practical and Political Hurdles

 
• By Cathy Kelly

Only a handful programs by pharmaceutical firms are in operation so far. Some companies may be waiting to see if a broad government-facilitated DTC initiative will materialize.

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 
• By Anju Ghangurde

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US, including potentially introducing new intermediaries into the system. Questions on MFN's feasibility and why it may be “catastrophic” to biopharma were also part of the discussion

More from Market Access

Changes In Pediatric COVID-19 Vaccine Recommendations Causing Coverage Confusion

 
• By Sue Sutter

The CDC’s current shared clinical decision-making recommendation for vaccinating healthy children age six months and older should trigger full coverage under the Affordable Care Act, but is not always happening at pharmacies and doctors’ offices, an Epstein Becker attorney said.

UK Drug Pricing Scheme Talks Collapse: Industry Braces For Another Year Of High Rebates

 
• By Eliza Slawther

Talks between the UK government and the pharmaceutical industry that were intended to resolve issues around high clawback rates under the voluntary pricing scheme for branded medicines have failed, meaning that the mechanism used to calculate rebates will remain in place.

Medicare Part D Plans Turn to Coinsurance, Higher Deductibles Amid IRA Changes

 
• By Tim Casey

Newly implemented IRA provisions may not necessarily lower drug costs for those enrolled in Medicare Part D plans, according to research by the USC Schaeffer Center for Health Policy and Economics.